The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
Open accessAbstract
In Rspondin-based 3D cultures, Lgr5 stem cells from multiple organs form ever-expanding epithelial organoids that retain their tissue identity. We report the establishment of tumor organoid cultures from 20 consecutive colorectal carcinoma (CRC) patients. For most, organoids were also generated from adjacent normal tissue. Organoids closely recapitulate several properties of the original tumor. The spectrum of genetic changes within the "living biobank" agrees well with previous large-scale mutational analyses of CRC. Gene expression analysis indicates that the major CRC molecular subtypes are represented. Tumor organoids are amenable to high-throughput drug screens allowing detection of gene-drug associations. As an example, a single organoid culture was exquisitely sensitive to Wnt secretion (porcupine) inhibitors and carried a mutation in the negative Wnt feedback regulator RNF43, rather than in APC. Organoid technology may fill the gap between cancer genetics and patient trials, complement cell-line- and xenograft-based drug studies, and allow personalized therapy design. PAPERCLIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“‘living biobanks’ can provide access to patient-derived cells and organoids from large patient cohorts, and have already been established for different cancers124,151,176–178, genetic diseases such as cystic fibrosis, infectious diseases, chronic obstructive pulmonary disease and inflammatory bowel diseases179”
From Human disease models in drug development (2023) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Organoids are ideally suited for FPM due to their ease of establishment, similarity with the tissue of origin and tractability158,167 and have been deployed to identify therapeutic leads in a number of tumors168, including rare cancers that tend to be understudied and poorly characterized at the molecular level16,151,169,170.”
From Organoids (2022) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies using in vitro organoids grown from different intestinal tumors [33, 34] showed a strong correlation, functionally and molecularly with their primary tissue counterparts, providing a strong argument in favor of the potential for in vitro systems to model intestinal disease.”
From Modeling APC mutagenesis and familial adenomatous polyposis using human iPS cells (2018) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In short, the wild-type human colon organoid line P26n, as previously described in Van De Wetering et al. (2015) was cultured in domes of Cultrex Pathclear Reduced Growth Factor Basement Membrane Extract (BME) (3533-001; Amsbio).”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as Van De Wetering et al. (2015)
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“broad clinical implementation of patient-specific disease models, such as PDOs, is currently hindered by low efficiencies in PDO establishment (60–70% success rate on average although, for some tissues, up to 90% have been reported for intestinal organoids151) as well as lengthy generation times and expansion procedures”
From Human disease models in drug development (2023) · cites this paper as [151]
The cited source says what the claim attributes to it.
In the citing paper
“Patient-derived tumor organoid (a.k.a. tumoroid) biobanks can be established from biopsies, surgical resections2,3, and even from Pap brushes4.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [3]
In the citing paper
“The reconstituted TME model recapitulates not only the genetic and phenotypic features of a tumor but also models the functional response of a patient to therapeutic agents [389, 390].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [389]
In the citing paper
“3D patient-derived tumor models of CRC (i.e., organoid and spheroid cultures) allow maintenance and expansion of functionally relevant cell subfractions and harbor the patients' individual genetic lesions (Ishiguro et al., 2017;van de Wetering et al., 2015).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as van de Wetering et al., 2015
In the citing paper
“Furthermore, with recent technological advancements (e.g. organoid models and conditionally reprogrammed cell lines), a new generation of cancer cell models is being derived to allow full representation of the histopathological and molecular diversity of tumours (37–42).”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Self-citationA genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Self-citationAdjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
Self-citation
Flagged first, then by citations
1 of the 64 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,001
Tumor organoids: From inception to future in cancer research
Yang, L., Yang, S., Li, X., Li, B., Li, Y., Zhang, X., Ma, Y., Peng, X., Jin, H., Fan, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.005 · Cited by 62
Engel, R. M., Chan, W. H., Nickless, D. K., Hlavca, S., Richards, E., Kerr, G., Oliva, K., McMurrick, P. J., Jardé, T., & Abud, H. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010128 · Cited by 59
Patient-derived organoids of non-small cells lung cancer and their application for drug screening
Li, Y., Gao, Y., Liang, B., Cao, X., Sun, Z., Yu, J. H., Liu, Z. D., & Han, Y. (2020) · Neoplasma · doi:10.4149/neo_2020_190417n346 · Cited by 61
Li, X., Larsson, P. G., Ljuslinder, I., Öhlund, D., Myte, R., Löfgren‐Burström, A., Zingmark, C., Ling, A., Edin, S., & Palmqvist, R. (2020) · Cancers · doi:10.3390/cancers12040923 · Cited by 64
A Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing
Saltsman, J. A., Hammond, W. J., Narayan, N. J. C., Requena, D., Gehart, H., Lalazar, G., LaQuaglia, M. P., Clevers, H. C., & Simon, S. M. (2020) · Cancers · doi:10.3390/cancers12092668 · Cited by 60
Self-citationBeato, F., Reverón, D., Dezsi, K. B., Ortiz, A. C., Johnson, J., Chen, D., Ali, K. N., Yoder, S., Jeong, D. K., Malafa, M. P., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00494-1 · Cited by 59
Wang, T., Pan, W., Zheng, H., Zheng, H., Wang, Z., Li, J. J., Deng, C., & Yan, J. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001971 · Cited by 59
Castro, F., Pereira, C. L., Macedo, M. H., Almeida, A., Silveira, M. J., Dias, S., Cardoso, A. P., Oliveira, M. J., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.06.001 · Cited by 62
Tan, P., Wang, M., Zhong, A., Wang, Y., Du, J., Wang, J., Qi, L., Bi, Z., Zhang, P., Lin, T., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01999-9 · Cited by 63
Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes
Meister, M. T., Koerkamp, M. J. A. G., de Souza, T. M., Breunis, W. B., Frazer‐Mendelewska, E., Brok, M. O., DeMartino, J., Manders, F., Calandrini, C., Kerstens, H. H. D., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216001 · Cited by 57
Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer
Bian, Y., Alem, D., Beato, F., Hogenson, T. L., Yang, X., Jiang, K., Cai, J., Ma, W. W., Fernández-Zapico, M. E., Tan, A. C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01300 · Cited by 60
Organoids in high-throughput and high-content screenings
Lampart, F. L., Iber, D., & Doumpas, N. (2023) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2023.1120348 · Cited by 61
Cellular self-assembly and biomaterials-based organoid models of development and diseases
Shah, S. B., & Singh, A. K. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.075 · Cited by 60
Fischer, M. M., Yeung, V. P., Cattaruzza, F., Hussein, R., Yen, W.-C., Murriel, C. L., Evans, J., O’Young, G., Brunner, A. L., Wang, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15704-y · Cited by 59
April-Monn, S., Wiedmer, T., Skowronska, M., Maire, R., Lena, M. S., Trippel, M., Domenico, A. D., Muffatti, F., Andreasi, V., Capurso, G., et al. (2020) · Neuroendocrinology · doi:10.1159/000507669 · Cited by 59
Pan‐Hammarström, Q., Zhong, S., Wang, H., Wang, X., Li, N., Li, Y., Zhang, G., Yuan, H., Lian, Y., Chen, Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.04.009 · Cited by 58
3D Cancer Models: Depicting Cellular Crosstalk within the Tumour Microenvironment
Franchi-Mendes, T., Eduardo, R., Domenici, G., & Brito, C. (2021) · Cancers · doi:10.3390/cancers13184610 · Cited by 59
SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4/CXCL12 axis
Fang, H., Huang, Y., Luo, Y., Tang, J., Yu, M., Zhang, Y., & Zhong, M. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104458 · Cited by 56
The future of tumor organoids in precision therapy
Kim, S., van de Wetering, M., Clevers, H. C., & Sanders, K. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.03.005 · Cited by 62
Self-citationNakamura, H., Sugano, M., Miyashita, T., Hashimoto, H., Ochiai, A., Suzuki, K., Tsuboi, M., & Ishii, G. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.007 · Cited by 57
Biological Significance of Tumor Heterogeneity in Esophageal Squamous Cell Carcinoma
Lin, L., & Lin, D. (2019) · Cancers · doi:10.3390/cancers11081156 · Cited by 58
Multiplexed single-cell analysis of organoid signaling networks
Sufi, J., Qin, X., Rodriguez, F. C., Bu, Y. J., Vlckova, P., Zapatero, M. R., Nitz, M., & Tape, C. J. (2021) · Nature Protocols · doi:10.1038/s41596-021-00603-4 · Cited by 54
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Cancer organoids: A platform in basic and translational research
Ma, X., Wang, Q. L., Li, G., Li, H., Xu, S., & Pang, D. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.052 · Cited by 62
Mayoh, C., Mao, J., Xie, J., Tax, G., Chow, S., Cadiz, R., Pazaky, K., Barahona, P., Ajuyah, P., Trebilcock, P., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3702 · Cited by 56
PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids
Liu, C., Banister, C. E., Weige, C. C., Altomare, D., Richardson, J. H., Contreras, C. M., & Buckhaults, P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802902115 · Cited by 57
Towards Multi-Organoid Systems for Drug Screening Applications
Miranda, C. C., Fernandes, T. G., Diogo, M. M., & Cabral, J. M. S. (2018) · Bioengineering · doi:10.3390/bioengineering5030049 · Cited by 58
Clinton, J., & McWilliams‐Koeppen, P. (2018) · Current Protocols in Cell Biology · doi:10.1002/cpcb.66 · Cited by 56
Newly established patient-derived organoid model of intracranial meningioma
Yamazaki, S., Ohka, F., Hirano, M., Shiraki, Y., Motomura, K., Tanahashi, K., Tsujiuchi, T., Motomura, A., Aoki, K., Shinjo, K., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab155 · Cited by 54
Emerging trends in the methodology of environmental toxicology: 3D cell culture and its applications
Wang, H., Xu, T., & Yin, D. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.159501 · Cited by 57
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy
Taurin, S., Alzahrani, R., Aloraibi, S., Ashi, L., AlHarmi, R. A. R., & Hassani, N. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102226 · Cited by 57
Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer
Xie, B., & Wu, A. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.191782 · Cited by 54
Usui, T., Sakurai, M., Enjoji, S., Kawasaki, H., Umata, K., Ohama, T., Fujiwara, N., Yabe, R., Tsuji, S., Yamawaki, H., et al. (2016) · Stem Cells International · doi:10.1155/2016/7053872 · Cited by 55
Gastric Organoids: An Emerging Model System to Study Helicobacter pylori Pathogenesis
Pompaiah, M., & Bartfeld, S. (2017) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-50520-6_7 · Cited by 56
Self-citationMochel, J. P., Jergens, A. E., Kingsbury, D. D., Kim, H. J., Martı́n, M. G., & Allenspach, K. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0178-1 · Cited by 55
Kidney organoids in translational medicine: Disease modeling and regenerative medicine
Miyoshi, T., Hiratsuka, K., Saiz, E. G., & Morizane, R. (2019) · Developmental Dynamics · doi:10.1002/dvdy.22 · Cited by 57
Organoid of ovarian cancer: genomic analysis and drug screening
Liu, H., Xia, B., Jin, M., & Lou, G. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02276-8 · Cited by 61
Choi, K.-Y. G., Wu, B. C., Lee, A. H., Baquir, B., & Hancock, R. E. W. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00228 · Cited by 54
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 55
Langenberg, K. P. S., Looze, E. J., & Molenaar, J. J. (2021) · Cancers · doi:10.3390/cancers13174324 · Cited by 61
CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis
Guo, Y., Zhu, Z., Huang, Z., Cui, L., Yu, W., Hong, W., Zhou, Z., Du, P., & Liu, C. (2022) · Nature Communications · doi:10.1038/s41467-022-32674-6 · Cited by 56
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold
Schmäche, T., Fohgrub, J., Klimová, A., Laaber, K., Drukewitz, S., Merboth, F., Hennig, A., Seidlitz, T., Herbst, F., Baenke, F., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01919-3 · Cited by 54
Wnt Signalling in Intestinal Stem Cells: Lessons from Mice and Flies
Perochon, J., Carroll, L. R., & Cordero, J. B. (2018) · Genes · doi:10.3390/genes9030138 · Cited by 55
The germline genetic component of drug sensitivity in cancer cell lines
Menden, M. P., Casale, F. P., Stephan, J., Bignell, G. R., Iorio, F., McDermott, U., Garnett, M. J., Sáez-Rodríguez, J., & Stegle, O. (2018) · Nature Communications · doi:10.1038/s41467-018-05811-3 · Cited by 54
Self-citationProgress in human liver organoids
Sun, L., & Hui, L. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa013 · Cited by 57
Biomaterials and Culture Systems for Development of Organoid and Organ-on-a-Chip Models
D’Costa, K. A., Kosic, M., Lam, A., Moradipour, A., Zhao, Y., & Radisic, M. (2020) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02498-w · Cited by 54
Shang, J., Zhu, Z., Chen, Y., Song, J., Huang, Y., Song, K., Zhong, J., Xu, X., Wei, J., Wang, C., et al. (2020) · Theranostics · doi:10.7150/thno.44043 · Cited by 55
Derouet, M. F., Allen, J., Wilson, G. W., Ng, C., Radulovich, N., Kalimuthu, S. N., Tsao, M., Darling, G. E., & Yeung, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-71589-4 · Cited by 54
Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors
Chen, C., Li, H.-W., Wang, Y., Lee, C.-C., Shen, Y.-C., Hsieh, C.-Y., Lin, H., Chen, X.-X., Cho, D., Hsieh, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20487-y · Cited by 54
Shu, D., Shen, M., Li, K., Han, X., Li, H., Tan, Z., Wang, Y., Peng, Y., Tang, Z., Qu, C., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2122550 · Cited by 53
Vertebrate centromeres in mitosis are functionally bipartite structures stabilized by cohesin
Sacristán, C., Samejima, K., Ruiz, L. A., Deb, M., Lambers, M. L. A., Buckle, A., Brackley, C. A., Robertson, D., Hori, T., Webb, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.014 · Cited by 70
Synthetic Lethality in Cancer Therapeutics
Beijersbergen, R. L., Wessels, L. F. A., & Bernards, R. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042016-073434 · Cited by 56
Self-citationA population genetics perspective on the determinants of intra-tumor heterogeneity
Hu, Z., Sun, R., & Curtis, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.001 · Cited by 54
Zhou, R., Xu, A., Gingold, J. A., Strong, L. C., Zhao, R., & Lee, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.004 · Cited by 52
Personalized Cancer Models for Target Discovery and Precision Medicine
Grandori, C., & Kemp, C. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.005 · Cited by 53
FGF Signalling in the Self-Renewal of Colon Cancer Organoids
Otte, J., Dizdar, L., Behrens, B., Goering, W., Knoefel, W. T., Wruck, W., Stoecklein, N. H., & Adjaye, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-53907-7 · Cited by 57
Berg, H. F., Hjelmeland, M. E., Lien, H. E., Espedal, H., Fonnes, T., Srivastava, A., Stokowy, T., Strand, E., Bozickovic, O., Stefansson, I. M., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00019-x · Cited by 59
BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer
Ramesh, P., Lannagan, T. R. M., Jackstadt, R., Atencia Taboada, L., Lansu, N., Wirapati, P., van Hooff, S. R., Dekker, D., Pritchard, J., Kirov, A. B., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00816-w · Cited by 52
Shimura, T., Sharma, P., Sharma, G. G., Banwait, J. K., & Goel, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-87283-y · Cited by 53
Rapid tissue prototyping with micro-organospheres
Wang, Z., Boretto, M., Millen, R., Natesh, N. R., Reckzeh, E. S., Hsu, C., Negrete, M., Yao, H., Quayle, W. B., Heaton, B. E., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.07.016 · Cited by 56
Self-citationMiyazaki, K., Xu, C., Shimada, M., & Goel, A. (2023) · Pharmaceuticals · doi:10.3390/ph16030383 · Cited by 52
Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
He, X., Jiang, Y. J., Zhang, L., Li, Y., Hu, X., Hua, G., Cai, S., Mo, S., & Peng, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1190637 · Cited by 56
Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma
Nakaoka, T., Saito, Y., & Saito, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061111 · Cited by 51
Cell and small animal models for phenotypic drug discovery
Szabo, M., Akusjärvi, S. S., Saxena, A., Liu, J., Chandrasekar, G., & Kitambi, S. S. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s129447 · Cited by 53
Pluripotent Stem Cell Platforms for Drug Discovery
Chen, K. G., Mallon, B. S., Park, K., Robey, P. G., McKay, R. D. G., Gottesman, M. M., & Zheng, W. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.009 · Cited by 53
Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncology
Dantes, Z., Yen, H.-Y., Pfarr, N., Winter, C., Steiger, K., Muckenhuber, A., Hennig, A., Lange, S., Engleitner, T., Öllinger, R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137809 · Cited by 53
Rapid Microfluidic Formation of Uniform Patient-Derived Breast Tumor Spheroids
Wu, Z., Gong, Z., Ao, Z., Xu, J., Cai, H., Muhsen, M., Heaps, S. R., Bondesson, M., Guo, S., & Guo, F. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00768 · Cited by 51
Evaluation of cancer immunotherapy using mini-tumor chips
Ao, Z., Cai, H., Wu, Z., Hu, L., Li, X., Kaurich, C., Gu, M., Liang Cheng, C., Lü, X., & Guo, F. (2022) · Theranostics · doi:10.7150/thno.71761 · Cited by 52
Shen, X., Zhang, Y., Xu, Z., Gao, H., Feng, W., Li, W., Miao, Y., Xu, Z., Zong, Y., Zhao, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04773-1 · Cited by 55
Cadherins and catenins in cancer: connecting cancer pathways and tumor microenvironment
Lin, W., Cooper, L. M., & Anastasiadis, P. Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1137013 · Cited by 60
Colorectal cancer models for novel drug discovery
Golovko, D. M., Kedrin, D., Yilmaz, Ö. H., & Roper, J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1079618 · Cited by 52
Modeling human disease using organotypic cultures
Schweiger, P. J., & Jensen, K. B. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.07.003 · Cited by 53
Emerging Opportunities for Target Discovery in Rare Cancers
Sharifnia, T., Hong, A. L., Painter, C., & Boehm, J. S. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.002 · Cited by 51
Tong, Z., Martyn, K., Yang, A. W., Yin, X., Mead, B. E., Joshi, N., Sherman, N. E., Langer, R., & Karp, J. M. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.038 · Cited by 55
Tamura, H., Higa, A., Hoshi, H., Hiyama, G., Takahashi, N., Ryufuku, M., Morisawa, G., Yanagisawa, Y., Ito, E., Imai, J., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6501 · Cited by 50
Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Lin, L., DeMartino, J., Wang, D., van Son, G. J. F., van der Linden, R., Begthel, H., Korving, J., Andersson-Rolf, A., van den Brink, S., Lopez-Iglesias, C., et al. (2023) · Science · doi:10.1126/science.adi2246 · Cited by 50
Self-citationPhysiologically relevant human tissue models for infectious diseases
Mills, M., & Estes, M. K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.020 · Cited by 50
The Contributions of Human Mini-Intestines to the Study of Intestinal Physiology and Pathophysiology
Yu, H. M., Hasan, N. M., In, J., Estes, M. K., Kovbasnjuk, O. N., Zachos, N. C., & Donowitz, M. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105211 · Cited by 51
Preclinical models for precision oncology
Ibarrola‐Villava, M., Cervantes, A. M. R., & Bardelli, A. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.004 · Cited by 50
Cao, W., Liu, J., Wang, L., Li, M., Verstegen, M. M. A., Yin, Y., Ma, B., Chen, K., Bolkestein, M., Sprengers, D., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy129 · Cited by 50
Ohata, H., Shiokawa, D., Obata, Y., Sato, A., Sakai, H., Fukami, M., Hara, W., Taniguchi, H., Ono, M., Nakagama, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.085 · Cited by 50
Li, S., Lavrijsen, M., Bakker, A., Magierowski, M., Magierowska, K., Liu, P., Wang, W., Peppelenbosch, M. P., & Smits, R. (2020) · Oncogene · doi:10.1038/s41388-020-1232-5 · Cited by 49
He, L., Dai, W., Xia, X., Wang, R., Zhao, J., Han, L., Mo, S., Xiang, W., Du, L., Zhu, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00957-4 · Cited by 50
Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
Sondorp, L. H. J., Ogundipe, V. M. L., Groen, A. H., Kelder, W., Kemper, A., Links, T. P., Coppes, R. P., & Kruijff, S. (2020) · Cancers · doi:10.3390/cancers12113212 · Cited by 51
Kleeman, S. O., & Leedham, S. J. (2020) · Cancers · doi:10.3390/cancers12113355 · Cited by 51
Hirokawa, Y., Clarke, J. E., Palmieri, M., Tan, T., Mouradov, D., Li, S., Lin, C., Li, F., Luo, H., Wu, K., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02607-y · Cited by 53
Gastrointestinal cancer organoids—applications in basic and translational cancer research
Seidlitz, T., & Stange, D. E. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00654-3 · Cited by 52
Patient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer
Cho, Y., Min, D., Kim, H., An, Y., Kim, S., Youk, J., Chun, J., Im, J. P., Song, S., Ju, Y. S., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13144 · Cited by 49
Chen, D., Su, X., Zhu, L., Hao, J., Han, B., Chen, H., Liang, Q., Hu, C., Yang, H., Liu, L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-022-03848-z · Cited by 50
Mafficini, A., Amato, E., Cataldo, I., Rusev, B. C., Bertoncello, L., Corbo, V., Simbolo, M., Luchini, C., Fassan, M., Cantù, C., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001999 · Cited by 49
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4434 · Cited by 55
Mini-gut: a promising model for drug development
Yin, Y., de Jonge, H. R., Wu, X., & Yin, Y. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.006 · Cited by 49
Salem, M. E., Battaglin, F., Goldberg, R. M., Puccini, A., Shields, A. F., Arguello, D., Korn, W. M., Marshall, J. L., Grothey, A. F., & Lenz, H. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0552 · Cited by 50
Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids
Choi, S. Y., Cho, Y., Kim, D., Ji, W., Choi, C., Lee, J. C., Rho, J. K., & Jeong, G. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031349 · Cited by 54
Human Organoids and Organs‐on‐Chips for Addressing COVID‐19 Challenges
Wang, Y., Wang, P., & Qin, J. (2022) · Advanced Science · doi:10.1002/advs.202105187 · Cited by 48
Kawasaki, M., Goyama, T., Tachibana, Y., Nagao, I., & Ambrosini, Y. M. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.895379 · Cited by 48
Fang, L., Ford-Roshon, D., Russo, M., O’Brien, C., Xiong, X., Gurjao, C., Grandclaudon, M., Raghavan, S., Corsello, S. M., Carr, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30794-7 · Cited by 49
Choosing wisely – Preclinical test models in the era of precision medicine
Klinghammer, K. F., Walther, W., & Hoffmann, J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.009 · Cited by 50
Potential Use of Human Stem Cell-Derived Intestinal Organoids to Study Inflammatory Bowel Diseases.
Dotti, I., & Salas, A. (2018) · Europe PMC (PubMed Central) · doi:10.1093/ibd/izy275 · Cited by 49
Metadata
- Authors
- van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., McLaren-Douglas, A., Blokker, J., Jaksani, S., Bartfeld, S., Volckman, R., van Sluis, P., Li, V. S. W., Seepo, S., Sekhar Pedamallu, C., Cibulskis, K., Carter, S. L., McKenna, A., Lawrence, M. S., Lichtenstein, L., Stewart, C., Koster, J., Versteeg, R., van Oudenaarden, A., Saez-Rodriguez, J., Vries, R. G. J., Getz, G., Wessels, L., Stratton, M. R., McDermott, U., Meyerson, M., Garnett, M. J., & Clevers, H.
- Affiliations
- Wellcome Sanger Institute (GB)
- Broad Institute (US)
- The Netherlands Cancer Institute (NL)
- European Bioinformatics Institute (GB)
- Diakonessenhuis hospital (NL)
- Royal Netherlands Academy of Arts and Sciences (NL)
- National Institute for Medical Research (GB)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Garnett, Mathew J.
- Clevers, Hans
- ORCID
- Francis, Joshua M.
- Iorio, Francesco
- Pronk, Apollo
- Taylor-Weiner, Amaro
- Kester, Lennart
- Bartfeld, Sina
- Li, Vivian S.W.
- Cibulskis, Kristian
- Carter, Scott L.
- McKenna, Aaron
- Lawrence, Michael S.
- Stewart, Chip
- Versteeg, Rogier
- Vries, Robert G.J.
- Getz, Gad
- Wessels, Lodewyk
- Stratton, Michael R.
- McDermott, Ultan
- Meyerson, Matthew
- Garnett, Mathew J.
- Clevers, Hans
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 4
- Pages
- 933-945
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6428276
- OpenAlex
- W1741548448
- Cited by
- 2,408
- References
- 64
- Citations by year
- 2026: 196 · 2025: 233 · 2024: 232 · 2023: 220 · 2022: 267 · 2021: 343 · 2020: 260 · 2019: 181 · 2018: 173 · 2017: 154 · 2016: 108 · 2015: 39
- FWCI
- 69.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- Francis Crick Institute (10105)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Keywords
- colorectal cancer, tumor organoids, organoid biobank, Lgr5+ stem cells, R-spondin, Wnt signaling, porcupine inhibitor, RNF43 mutation, APC mutation, drug screening, personalized treatment, molecular subtypes, gene expression profiling
- MeSH terms
- DNA-Binding Proteins, Drug Screening Assays, Antitumor, Humans, Organ Culture Techniques, Organoids, Colorectal Neoplasms, Oncogene Proteins, Biological Specimen Banks, Ubiquitin-Protein Ligases, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
